Slow Start For ‘Blockbuster’ Heart Failure Drug Entresto

Entresto, the new heart failure drug from Novartis that is widely expected to be a blockbuster, is off to an exceptionally slow start. Approved last July, the drug, formerly known as LCZ 696, had sales of only $21 million in 2015, only $5 million of which came in the fourth quarter. Despite low expectations in the early...Click here to continue reading...

Source: CardioBrief - January 28, 2016 Category: Cardiology Authors: Larry Husten Tags: Heart Failure People, Places & Events Uncategorized Entresto LCZ 696 Source Type: blogs